Releases
KTTAW
--
0.00%
--
  • All
  • Financials
  • Insiders
More
Webull provides the latest Pasithea Therapeutics Corp (KTTAW) stock and general news. This information may help you make smarter investment decisions.
About KTTAW
Pasithea Therapeutics Corp. is a biotechnology company. The Company is engaged on psychiatric and neurological research regarding central nervous system (CNS) disorders with focus on translating the research into clinic-ready drugs. The Company's secondary operations are focused on establishing anti-depression clinics across the United Kingdom and providing business support services to similar entities in the United States and using psychiatric assessment combined with physician or medical providers to administer intravenous infusions of ketamine.